NCT03622125 is a clinical trial of Vital signs in Scorpion Stings, sponsored by Mexican Red Cross.

Who is sponsoring NCT03622125?

NCT03622125 is sponsored by Mexican Red Cross.

What drugs are being tested in NCT03622125?

Interventions in NCT03622125: Vital signs.

What condition does NCT03622125 study?

NCT03622125 studies Scorpion Stings.

Is NCT03622125 still recruiting?

NCT03622125 is currently completed. Last updated 15 August 2019.

Last reviewed 2019-08-15 · How we verify

NCT03622125

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Decrease in Temperature as a Pagtonomic Sign by Scorpion Sting

Completed Last updated 15 August 2019

What this trial tests

trial testing Vital signs in Scorpion Stings in 184 participants. Completed in 30 July 2017.

Timeline

20 May 2017

Primary endpoint
15 June 2017

30 July 2017

Quick facts

Lead sponsor	Mexican Red Cross
Status	Completed
Study type	OBSERVATIONAL
Enrollment	184
Start date	20 May 2017
Primary completion	15 June 2017
Estimated completion	30 July 2017
Sites	1 location across Mexico

Drugs / interventions tested

Vital signs — full drug profile →

Conditions studied

Scorpion Stings — all drugs for Scorpion Stings →

Sponsor

Mexican Red Cross

Who can join

Adults 3 to 90, any sex, with Scorpion Stings. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The scorpion sting is a medical disease, for the signs and symptoms presented; Sometimes patients do not know the animal that causes these symptoms; the bibliography marks the decrease in temperature as a sign to be presented.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Vital signs

Trials testing the same drug.

NCT07372859 — Women's Heart: Impact of Ultra-endurance and Hormonal Profile on Cardiac and Systemic Inflammatory Parameters in Female · NA · not yet recruiting
NCT06812221 — Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI · Phase 1, PHASE2 · completed
NCT05037162 — Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19 · Phase 2 · completed
NCT05272969 — Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease · unknown
NCT05576740 — Influence of Menstrual Cycle Stages on Female Athletes · completed

Other Mexican Red Cross trials

Trials by the same sponsor.

NCT03943199 — Comparison of Lysine Clonixinate, Ketorolac and Metamizole Sodium in Scorpion Stings · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03622125 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mexican Red Cross
Last refreshed: 15 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03622125.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing